Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for... correspondence A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox To the Editor — Monkeypox virus, in Post-exposure prophylaxis (PEP) with 28 days of the first vaccine dose. Secondary the genus Orthopoxvirus, causes regular MVA-BN vaccine has been recommended objectives include assessment of humoral outbreaks of disease in endemic areas of recently by several countries in Europe response by measurement of antibody titers 1 8 Central and West Africa . Since 13 May and North America . PEP has been used against orthopoxvirus by serology and 2022, cases of monkeypox have been for past imported outbreaks, but there are neutralization on the day of the first dose; reported in European countries and North limited data on its efficacy, some of which at 7 days, 14 days and 28 days after the first America, outnumbering the imported are from animal challenge models . In the dose; after the second dose (43 days); and at cases from previous outbreaks outside UK outbreak in 2018, 3 cases were declared 3 months after the second dose. The study endemic countries . Previous imported and 154 contacts were identified (including will also evaluate factors associated with cases have included 71 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Medicine Springer Journals

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/a-prospective-national-cohort-evaluating-ring-mva-vaccination-as-post-LbF2ufPLUq

References (6)

Publisher
Springer Journals
Copyright
Copyright © Springer Nature Limited 2022
ISSN
1078-8956
eISSN
1546-170X
DOI
10.1038/d41591-022-00077-1
Publisher site
See Article on Publisher Site

Abstract

correspondence A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox To the Editor — Monkeypox virus, in Post-exposure prophylaxis (PEP) with 28 days of the first vaccine dose. Secondary the genus Orthopoxvirus, causes regular MVA-BN vaccine has been recommended objectives include assessment of humoral outbreaks of disease in endemic areas of recently by several countries in Europe response by measurement of antibody titers 1 8 Central and West Africa . Since 13 May and North America . PEP has been used against orthopoxvirus by serology and 2022, cases of monkeypox have been for past imported outbreaks, but there are neutralization on the day of the first dose; reported in European countries and North limited data on its efficacy, some of which at 7 days, 14 days and 28 days after the first America, outnumbering the imported are from animal challenge models . In the dose; after the second dose (43 days); and at cases from previous outbreaks outside UK outbreak in 2018, 3 cases were declared 3 months after the second dose. The study endemic countries . Previous imported and 154 contacts were identified (including will also evaluate factors associated with cases have included 71

Journal

Nature Medicine – Springer Journals

Published: Oct 1, 2022

Keywords: Public health; Clinical trials; Vaccines; Virology

There are no references for this article.